top of page

Investor_Relations

NOVUS strives to serve the communities and create values for our trustworthy and passionate investors.

NOVUS was established in 2014 with a clear mission to become a trailblazer in the realm of cutting-edge biomaterials for clinical applications. Over the years, we have dedicated ourselves to creating significant value for both our esteemed investors and society as a whole. During our formative stages, NOVUS received unwavering support from respected statutory bodies across various countries, in addition to investments from prominent angels and venture capitalists worldwide. These crucial partnerships have propelled us forward, allowing NOVUS to expand into a group of companies engaged in diverse activities such as biomaterials research and development, manufacturing, contract research, and technology consultancy. Our multifaceted roles enable us to stay at the forefront of the fast-paced technology landscape, continuously adapting to industry advancements.

With a solid foundation firmly in place, NOVUS remains committed to establishing a robust presence in the healthcare and technology sectors. We are driven by a relentless pursuit of innovation, leveraging our expertise and experience to deliver groundbreaking solutions. Our unwavering dedication to pushing boundaries and making a lasting impact sets us apart. As we move forward, we strive to further strengthen our position in the industry, driving transformative change and revolutionizing the intersection of healthcare and technology.

#Supporting_statutory_bodies, Partners_and_prizes

Invest HK, support team

Ernst & Young

EY x Fosun Challenge, Shanghai, 2018 - NOVUS won in the EY x Fosun Challenge in Shanghai and won a pilot project with Fosun.

Invest HK, support team

Fosun

EY x Fosun Challenge, Shanghai, 2018 - NOVUS won in the EY x Fosun Challenge in Shanghai and won a pilot project with Fosun.

Invest HK, support team

Alibaba Jumpstarter

Jumpstarter is an entrepreneurship programme launched by Alibaba. In 2017, NOVUS won in the Healthcare stream.

Invest HK, support team

CNBC

NOVUS was selected by CNBC as 20 of the world’s hottest start-ups of 2014.

Invest HK, support team

Austria Wirtschaftsservice

AWS and FFG, the government technology and innovation agencies in Austria has selected NOVUS to join goAustria 2016.

Invest HK, support team

e27

Invest HK, support team

Hong Kong Science and Technology Parks

NOVUS is a graduate of HKSTP incu-bio programme in 2018. Ossfila is a graduate of HKSTP incu-tech programme in 2022.

Invest HK, support team

Dreamcatchers, the University of Hong Kong

HKU Dreamcatchers has supported NOVUS and Ossfila to kick-start the commerilization of deep-tech biomaterial technologies.

Invest HK, support team

Global Incubator Network Austria (GIN)

GIN is the connecting link between Austrian and international startups, investors, incubators and accelerators. NOVUS represented Hong Kong in 2016.

Invest HK, support team

SOW Asia

NOVUS Life Sciences has been selected to join the Biotechnology and Wellbeing cohort of SOW Asia's i2i (Incubation to Investment) accelerator program.

Invest HK, support team

ImagineIF

In 2016, Innovation Forum has selected NOVUS has the HONG KONG champion and Global top 15 to present in the University of Cambridge, UK.

Invest HK, support team

French Tech Ticket

French Tech Ticket is a French national tech startup programme. In 2017, NOVUS has won the ticket and participated in the programme.

Invest HK, support team

Innovation and Technology Commission, HKSARG

Innovation and Technology Commission has been supporting the R&D activities of NOVUS.

Invest HK, support team

Global Entrepreneurship Week (GEW 50)

NOVUS was a GEW50 finalist in 2014.

Invest HK, support team

IPIEC Global

The winner of the IPIEC Global 2018. NOVUS was ultimately awarded the annual global overall championship winning a reward of HK$780,000.

Invest HK, support team

Innovation Forum

In 2016, Innovation Forum has selected NOVUS has the HONG KONG champion and Global top 15 to present in the University of Cambridge, UK.

bottom of page